Formycon And OneSource Specialty Pharma Partner To Manufacture Biosimilars

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.

Explore Firm Details

Formycon AG has announced a strategic manufacturing partnership with OneSource Specialty Pharma Limited to enhance its biosimilar development capabilities. The collaboration brings together Formycon's biosimilar expertise with OneSource's integrated biologics manufacturing platform in Bangalore, India. With three biosimilars already on the U.S. market and four pipeline candidates in development, this partnership aims to strengthen Formycon's position in the competitive biosimilar landscape.

United States Food, Drugs, Healthcare, Life Sciences

Michael Shriner

Article Insights

Michael Shriner’s articles from Goodwin Procter LLP are most popular:

within Food, Drugs, Healthcare and Life Sciences topic(s)
in United States
with readers working within the Business & Consumer Services industries

Goodwin Procter LLP are most popular:

within Criminal Law topic(s)

Formycon AG (“Formycon”) announced its partnership with OneSource Specialty Pharma Limited (“One Source”) on July 14, 2026. OneSource, located in Bangalore, India, will complement Formycon’s biosimilar development experience with its biologics manufacturing capabilities. OneSource has an integrated biologics platform that ranges from cell line development to commercial fill-finish and five manufacturing facilities. Currently, Formycon has three biosimilars on the U.S. market (FYB201/ranibizumab, FYB202/ustekinumab, and FYB203/aflibercept) and four pipeline candidates in development (including FYB206/pembrolizumab and FYB208/dupilumab).

Stay tuned to the Big Molecule Watch for more!

The post Formycon and OneSource Specialty Pharma Partner to Manufacture Biosimilars appeared first on Big Molecule Watch.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Authors

Formycon And OneSource Specialty Pharma Partner To Manufacture Biosimilars

Contributor

Food, Drugs, Healthcare, Life Sciences

Contributor

United States